Inferra AI / Company / TGTX
Tg Therapeutics, Inc.
TGTX · Health Care
Last earnings Aug 3, 2026
Key results
Revenuequarter
$141.1 million
revenue of $141.1 million, including BRIUMVI U.S. net
SEC original ↗Tg Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Revenuefull-year
$138.8 million
net revenue of $138.8 million Raises full year 2025 BRIUMVI U.
SEC original ↗Tg Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
net revenue target to approximately $570 - $575 million Conference call to be held today, Monday, August 4, 2025, at 8:30 AM ET New York, NY, (August 4, 2025 ) TG Therapeutics, Inc.
SEC original ↗Tg Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
net product revenue of $138.8 million for the second quarter of 2025, representing 91% growth over the same period last year and 16% growth over Q1 2025 Expansion of commercialization outside of the U.
SEC original ↗Tg Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
revenue of $138.8 million for the second quarter of 2025, representing 91% growth over the same period last year and 16% growth over Q1 2025 Expansion of commercialization outside of the U.S. with our partner, Neuraxpharm, with BRIUMVI approved in the European Union, United Kingdom
SEC original ↗Tg Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
License, milestone, royalty and other revenue: License, milestone, royalty and other revenue was approximately $2.3 million and $3.5 million for the three and six months ended June 30, 2025, respectively, compared to approximately $0.9 million and $13.9 million for the three and six months ended June 30, 2024.
SEC original ↗Tg Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Net incomequarter
$28.2 million
Net Income (Loss): Net income was $28.2 million and $33.2 million for the three and six months ended June 30, 2025, respectively, compared to net income (loss) of $6.9 million and $(3.8) million for the three and six months ended June 30, 2024 respectively.
SEC original ↗Tg Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
AI analysis
Q2 2025 · reported Aug 4, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $141.1 million | — | — |
| Net income | $28.2 million | — | — |
Guidance · company-stated
Direction: raised
No guidance located in the held release
“BRIUMVI in Myasthenia Gravis Announced positive topline phase 1 data for subcutaneous BRIUMVI in patients with myasthenia gravis (MG) Initiated a potentially registration-directed randomized phase 2 clinical trial evaluating IV BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with MG BRIUMVI in Schizophrenia Initiated a Phase 2 clinical trial evaluating BRIUMVI in adults with treatment-resistant schizophrenia 2026 Financial Guidance Update Raises full year 2026 target total global revenue to approximately $950 million Raises full year 2026 target BRIUMVI U.”
Capital allocation
Our level of indebtedness and debt service obligations could adversely affect our financial condition and may make it more difficult for us to fund our operations.
NOTE 3 - INVESTMENT SECURITIES The Company s investment securities as of June 30, 2026 and December 31, 2025 primarily consist of government debt securities that are classified as held-to-maturity.
Event summary
TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
Our level of indebtedness and debt service obligations could adversely affect our financial condition and may make it more difficult for us to fund our operations.
SEC original ↗Tg Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
NOTE 3 - INVESTMENT SECURITIES The Company s investment securities as of June 30, 2026 and December 31, 2025 primarily consist of government debt securities that are classified as held-to-maturity.
SEC original ↗Tg Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Strategy & priorities
The strong uptake we re seeing, combined with deepening physician confidence and compelling patient experiences, underscores the strength of our launch strategy and gives us confidence in reaching our updated 2025 full year BRIUMVI U.
SEC original ↗Tg Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
net product revenue of $138.8 million for the second quarter of 2025, representing 91% growth over the same period last year and 16% growth over Q1 2025 Expansion of commercialization outside of the U.
SEC original ↗Tg Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
1 ABOUT TG THERAPEUTICS TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.
SEC original ↗Tg Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Risks Related to Governmental Regulation of the Pharmaceutical Industry and Legal Compliance Matters We are subject to new legislation, regulatory proposals and third-party payor initiatives that may increase our costs of compliance and adversely affect our ability to market our products, obtain collaborators and raise capital.
SEC original ↗Tg Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Risks Related to Our Business Organization and Governance, Strategy, Employees and Growth Management If we fail to attract and keep key management, commercial, and clinical development personnel, we may be unable to successfully develop or commercialize our product and product candidates.
SEC original ↗Tg Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Risks & headwinds
Cautionary Statement This press release contains forward-looking statements that involve a number of risks and uncertainties.
SEC original ↗Tg Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release.
SEC original ↗Tg Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our other filings with the SEC.
SEC original ↗Tg Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements.
SEC original ↗Tg Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
They involve risks, uncertainties and assumptions.
SEC original ↗Tg Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any drug candidates that we may develop.
SEC original ↗Tg Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
31 documents- Q2 2026
- 10-QTGTX
- 8-KTGTX
Aug 3, 2026
- Q1 2026
- 8-KTGTX
Jun 12, 2026
- 8-KTGTX
Jun 3, 2026
- 8-KTGTX
May 27, 2026
- 10-QTGTX
- 8-KTGTX
May 6, 2026
- Q4 2025
- 8-KTGTX
Mar 20, 2026
- 10-KTGTX
Feb 27, 2026
- 8-KTGTX
Feb 26, 2026
- 8-KTGTX
Jan 13, 2026
- EX-99TGTX
Jan 13, 2026
- Q3 2025
- 10-QTGTX
- 8-KTGTX
Nov 3, 2025
- Q2 2025
- 10-QTGTX
- 8-KTGTX
Aug 4, 2025
- Q1 2025
- 8-KTGTX
Jun 13, 2025
- 10-QTGTX
- 8-KTGTX
May 5, 2025
- Q4 2024
- 10-KTGTX
Mar 3, 2025
- 8-KTGTX
Mar 3, 2025
- 8-KTGTX
Jan 14, 2025
- Q3 2024
- 10-QTGTX
- 8-KTGTX
Nov 4, 2024
- Q2 2024
- 10-QTGTX
- 8-KTGTX
Aug 6, 2024
- Q1 2024
- 8-KTGTX
Jun 17, 2024
- 10-QTGTX
- 8-KTGTX
May 1, 2024
- Q4 2023
- 10-KTGTX
Feb 29, 2024
- 8-KTGTX
Feb 28, 2024
Earnings releases
13 documentsPresentations
0 documentsNo presentations for Tg Therapeutics, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Tg Therapeutics, Inc. are held in this edition of the library.
Mentioned by
4 companiesOther tracked companies whose held documents mention Tg Therapeutics, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
“…TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments”
“…TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments”
“…TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments”
“…TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments”
See also the earnings calendar for every tracked company’s next earnings date.